Isomorphic Labs Secures $2.1 Billion to Scale AI Drug Discovery…

Team S · 2026-05-12T15:27:11.000Z

🇬🇧 London-based AI drug discovery startup Isomorphic Labs has secured $2.1 billion in fresh funding as the Google DeepMind spinout accelerates development of its AI-powered drug design engine and expands globally. The funding round was led by Thrive Capital, with participation from Alphabet, further strengthening investor confidence in one of the world’s most advanced AI-driven biotech companies. Founded by DeepMind CEO and Nobel Prize-winning AI researcher Demis Hassabis, Isomorphic Labs was spun out of Google DeepMind in 2021 to commercialize breakthrough AI systems for biology and pharmaceutical research. The company builds on AlphaFold, DeepMind’s landmark AI model capable of predicting protein structures with unprecedented accuracy, which has become one of the most influential technologies in modern computational biology. The new funding will be used to scale the company’s AI drug design infrastructure, expand scientific and engineering teams, and accelerate partnerships with major pharmaceutical companies globally. Isomorphic Labs has already established collaborations with Eli Lilly, Novartis, and other major biotech and pharma players as it pushes toward using generative AI to dramatically reduce the time and cost required for discovering new medicines. The company recently introduced its proprietary Drug Design Engine, a next-generation AI platform designed to improve molecular prediction, protein-ligand interaction analysis, and therapeutic discovery workflows beyond AlphaFold 3 capabilities. According to the company, the platform significantly improves biological modeling accuracy while reducing computational complexity and development timelines. The funding highlights growing global investor interest in AI-native biotechnology startups as pharmaceutical companies increasingly adopt machine learning systems for drug discovery, molecular simulation, protein engineering, and precision medicine. The deal also reinforces Alphabet’s broader strategy of commercializing advanced AI research through standalone businesses across healthcare, robotics, and infrastructure.

Member Login Get Access

Isomorphic Labs Secures $2.1 Billion to Scale AI Drug Discovery… | Newnex